The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial

SIMPLE SUMMARY: Anthracycline and taxane-based chemotherapy are the cornerstone of adjuvant therapy for early breast cancer. In recent years, several trials explored the efficacy of the anthracycline-free regimens, especially for HER2-negative breast cancer patients, which turned out to be a feasibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Deyue, Wu, Jiayi, Lin, Caijin, Ding, Shuning, Lu, Shuangshuang, Fang, Yan, Huang, Jiahui, Hong, Jin, Gao, Weiqi, Zhu, Siji, Chen, Xiaosong, Huang, Ou, He, Jianrong, Chen, Weiguo, Li, Yafen, Shen, Kunwei, Zhu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264845/
https://www.ncbi.nlm.nih.gov/pubmed/35804991
http://dx.doi.org/10.3390/cancers14133221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264845/
https://www.ncbi.nlm.nih.gov/pubmed/35804991
http://dx.doi.org/10.3390/cancers14133221

Ejemplares similares